INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

被引：0

作者：

Baquerizo, Angeles ^{[1
,2
]}

Vavinskaya, Vera ^{[3
]}

Rojas, Angela ^{[4
]}

Mhoyan, Anna ^{[5
]}

Romero-Gomez, Manuel ^{[6
]}

Sher, Linda ^{[7
]}

Madani, Bahar ^{[2
]}

Fisher, Jonathan ^{[1
]}

Schaffer, Randolph ^{[1
]}

Frenette, Catherine T. ^{[8
]}

Marsh, Christopher ^{[9
]}

机构：

[1] Scripps Hlth, Surg, La Jolla, CA USA

[2] Scripps Clin, La Jolla, CA 92037 USA

[3] UCSD, Pathol, La Jolla, CA USA

[4] Virgen Del Rocio Univ Hosp, Hepatol, Seville, Spain

[5] Kaiser, Pathol, San Diego, CA USA

[6] Virgen Del Rocio Univ Hosp, Seville, Spain

[7] USC, Los Angeles, CA USA

[8] Scripps Hlth, Scripps Clin, La Jolla, CA USA

[9] Scripps Hlth, La Jolla, CA USA

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

321

引用

页码：206A / 206A

页数：1

共 50 条

[41] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, Durre
Zaheer, Samreen
Sureka, Niti
Trisal, Monal
Chaurasia, Jai Kumar
Zaheer, Sufian
PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
[42] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
Maslanka, A.
Kitel, R.
Konopka, J.
Skalniak, L.
FEBS OPEN BIO, 2024, 14 : 329 - 330
[43] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, Mario
Indraccolo, Stefano
Zagonel, Vittorina
Lombardi, Giuseppe
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
[44] Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 314 - 331
[45] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
Ribatti, Domenico
Cazzato, Gerardo
Tamma, Roberto
Annese, Tiziana
Ingravallo, Giuseppe
Specchia, Giorgina
FRONTIERS IN ONCOLOGY, 2024, 14
[46] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, Kathleen M.
Freeman, Gordon J.
McDermott, David F.
CLINICAL THERAPEUTICS, 2015, 37 (04) : 764 - 782
[47] PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Peng, Zikun
Li, Ming
Li, Huayi
Gao, Qinglei
DRUG DISCOVERY TODAY, 2023, 28 (08)
[48] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Yanting
Li, Hongyan
FRONTIERS IN NEUROSCIENCE, 2023, 17
[49] PD-1/PD-L1 immune checkpoint in bone and soft tissue tumors (Review)
Hashimoto, Kazuhiko
Nishimura, Shunji
Goto, Koji
MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (04)
[50] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
AmeliMojarad, Mandana
AmeliMojarad, Melika
Cui, Xiaonan
PATHOLOGY RESEARCH AND PRACTICE, 2023, 244

← 1 2 3 4 5 →